<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55014133"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<reference>Free Radical Biology &amp; Medicine, Vol. 20, No. 5, pp. 675-705, 1996<lb/></reference>

	<note type="copyright">Copyright &#169; 1996 Elsevier Science Inc.<lb/> Printed in the USA. All rights reserved<lb/></note>

	<note>0891.5849/96 $15.00 + .OO<lb/> </note>

	<note type="other">ELSEVIER<lb/> </note>

	<note>0891~5849(95)02110-8<lb/> -+<lb/></note>
	
	<note type="other">Review Article<lb/></note>

	<docTitle>
	<titlePart>CHARACTERIZATION OF DRUGS AS ANTIOXIDANT<lb/> PROPHYLACTICS<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>OKEZIE I. ARUOMA<lb/></docAuthor>
	</byline>

	<byline>
	<affiliation>Pharmacology Group, University of London King&apos;s College,</affiliation>
	</byline>

	<address>London, UK<lb/></address>

	<note type="submission">(Received 24 May 1995; Revised 28 August 1995; Accepted 31 August 1995)<lb/></note>

	<div type="abstract">Abstract-There<lb/> is growing interest in the evaluation of drugs (prescription only medicines and over-the-counter<lb/> medicines) as antioxidant prophylactics. Although free radical mechanism in human degenerative diseases is now<lb/> generally recognised, the mechanisms of tissue injury in humans are very complex and it may not be possible to<lb/> clearly identify the role played by free radicals in the process. This review examines the current evidence to<lb/> support the notion that drugs for a particular therapeutic category might possess useful antioxidant capacity hence<lb/> rninimising tissue injury due to free radicals.<lb/></div>

	<keyword>Keywords-Free<lb/> radicals, Oxidative stress, Human diseases, Antioxidants, Drug design<lb/></keyword>

		</front>
	</text>
</tei>
